Selecting initial treatment of acute myeloid leukaemia in older adults
Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Reviews 2016, 31: 43-62. PMID: 27745715, DOI: 10.1016/j.blre.2016.09.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaTreatment-related mortalityInduction chemotherapyComplete remissionInitial treatmentMyeloid leukemiaNovel agentsOlder adultsMedian overall survivalGroup of patientsPhase III developmentDisease-related characteristicsMechanism of actionCPX-351Overall survivalLow-intensity treatmentClinical trialsTreatment outcomesPatientsRemissionChemotherapyLeukemiaMortalityTreatmentAdultsLost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes
Stahl M, Gore SD, Vey N, Prebet T. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Expert Opinion On Investigational Drugs 2016, 25: 307-317. PMID: 26807602, DOI: 10.1517/13543784.2016.1146251.BooksMeSH KeywordsAnimalsAntineoplastic AgentsDrug DesignEpigenesis, GeneticHistone Deacetylase InhibitorsHumansLeukemia, Myeloid, AcuteMutationMyelodysplastic SyndromesPatient SelectionConceptsHistone deacetylase inhibitorsAcute myeloid leukemiaMyeloid malignanciesMyelodysplastic syndromeMyeloid leukemiaDeacetylase inhibitorsSelection of patientsFuture clinical developmentClinical resultsDNA methyltransferase inhibitorClinical developmentSingle agentHDAC inhibitorsRobust biomarkersPleiotropic activitiesMalignancyPotential targetCancer therapyMethyltransferase inhibitorSyndromeLeukemiaInhibitorsEpigenetic modifiersEpigenetic changesMyeloma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply